We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ORK:EURONEXT OSLOOrkla ASA Analysis

Data as of 2026-03-14 - not real-time

NOK 118.60

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Orkla ASA trades at NOK 118.6, comfortably above its 20‑day SMA of 125.9 and 50‑day SMA of 119.4, signaling a short‑term bullish bias despite a RSI of 38.5 that hints at modest oversold conditions. The MACD histogram is negative and the signal line is bullish, suggesting that momentum may be weakening in the near term. Support sits near 116.8, just below the current price, while resistance at 131.2 offers a clear upside target. Valuation metrics show a forward P/E of 16.4 and a dividend yield of 3.4%, with a payout ratio under 63%, indicating that the dividend is well‑covered by free cash flow. The DCF fair value of 42.8 appears out of line with market pricing, but the modest upside/downside estimate of 3.4% suggests the market is only slightly above intrinsic expectations. With a low beta (near zero) and a 30‑day volatility of 28%, the stock exhibits defensive characteristics typical of its consumer‑defensive sector. Fundamentally, Orkla delivers solid ROE (~13%) and stable operating margins despite flat revenue growth. The balance sheet shows a moderate debt‑to‑equity of 32% and ample cash generation, reinforcing financial resilience. Overall, the company presents a stable income‑oriented profile with limited upside but attractive yield, making it suitable for investors seeking defensive exposure and reliable dividends.
In the short term, price action is constrained by bearish MACD momentum and a modest RSI, warranting a cautious hold stance. Over the medium horizon, the fair valuation, defensive sector positioning, and sustainable dividend support a neutral to slightly positive outlook. For long‑term investors, the combination of low volatility, consistent cash flow, and attractive yield underpins a buy recommendation, especially for income‑focused portfolios.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term SMA but bearish MACD histogram
  • Support level near 116.8 providing downside cushion
  • RSI indicating slight oversold condition

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Fair valuation with modest upside potential
  • Stable dividend yield and sustainable payout ratio
  • Defensive consumer‑defensive sector reduces earnings volatility

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Consistent dividend income and low payout risk
  • Low beta and defensive sector provide resilience
  • Solid ROE and cash flow generation support long‑term stability

Key Metrics & Analysis

Financial Health

Revenue Growth-0.10%
Profit Margin16.04%
P/E Ratio18.4
ROE13.40%
ROA5.27%
Debt/Equity32.10
P/B Ratio2.4
Op. Cash FlowNOK9.3B
Free Cash FlowNOK4.2B

Technical Analysis

TrendBullish
RSI38.5
SupportNOK 116.80
ResistanceNOK 131.20
MA 20NOK 125.90
MA 50NOK 119.39
MA 200NOK 111.12
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueNOK 42.76
Target PriceNOK 122.60
Upside/Downside3.37%
GradeFair
TypeValue
Dividend Yield3.40%

Risk Assessment

Beta-0.09
Volatility28.34%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.